by | Feb 12, 2024 | Myeloma News
Source: Pharmacy Times articles In addition to improved progression-free survival, patients treated with this regimen also showed improved complete response or stronger and were minimal residual disease-negative. Read More
by | Feb 12, 2024 | Myeloma News
Researchers around the world share results from a novel model that can provide tailored predictions of how individual patients respond to different therapies. Read More
by | Feb 9, 2024 | Myeloma News
Source: Pharmacy Times articles Patients readily accepted physical interventions and referrals to oncology clinical pharmacy practitioners. Read More
by | Feb 7, 2024 | Myeloma News
Source: Pharmacy Times articles Gabriel Hinojosa, PharmD, BCOP, looks beyond frontline regimens in multiple myeloma, and discusses treatment options, adverse events, and complexities in sequencing therapies. Read More
by | Feb 7, 2024 | Myeloma News
Source: Pharmacy Times articles Treatment decisions should depend on the patient, their disease, and their disease progression. Read More
by | Feb 6, 2024 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
